News

Video

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

Author(s):

Preet M. Chaudhary, MD, PhD,Noah Merin, MD, PhD

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

Related Videos
Tracy George, MD
Elias Jabbour, MD
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Related Content
ASH Annual meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 13th 2024

100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Ponatinib Risk Management in CML/ALL | Image Credit: © ivlianna stock.adobe.com
December 11th 2024

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

Mark Agulnik, MD, professor, clinical medicine, vice chair, faculty development, Department of Medicine, section chief, Sarcomas & Melanoma, Keck School of Medicine, the University of Southern California
June 24th 2024

Agulnik Highlights Key Updates in GIST Research and Management

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 11th 2024

Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis

Polycythemia Vera | Image Credit: © ChaoticMind – stock.adobe.com
December 11th 2024

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET